about
Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, GuineaEarly and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys.Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.Production of CXC and CC chemokines by human antigen-presenting cells in response to Lassa virus or closely related immunogenic viruses, and in cynomolgus monkeys with lassa fever.Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophagesExonuclease domain of the Lassa virus nucleoprotein is critical to avoid RIG-I signaling and to inhibit the innate immune response.The exonuclease domain of Lassa virus nucleoprotein is involved in antigen-presenting-cell-mediated NK cell responses.NK cells are strongly activated by Lassa and Mopeia virus-infected human macrophages in vitro but do not mediate virus suppression.Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs.A vaccine platform against arenaviruses based on a recombinant hyper-attenuated Mopeia virus expressing heterologous glycoproteins.Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategiesLassa virus activates myeloid dendritic cells but suppresses their ability to stimulate T cellsNon-Pathogenic Mopeia Virus Induces More Robust Activation of Plasmacytoid Dendritic Cells than Lassa VirusImmune parameters and outcomes during Ebola virus diseaseVaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot
P50
Q29247868-44A16C2B-E150-4B22-B684-EC92C63F1947Q33383772-948D7559-8A6A-4940-8304-54E470B29DDFQ35140402-F4114430-BD27-4B9C-87EC-0CAD0B7DCE9CQ37464889-74AE27C8-6202-4C83-ADFC-AF9D385C9DBDQ38959283-F6C5D575-4C65-4C0D-A8A4-CD5C3972AD30Q40189585-EA85BE28-EE4D-4854-A769-C4D8C7CCC644Q40189592-4D56108A-8404-437F-BDF0-B3BA72B7F76BQ40287006-C3AD5147-EBC3-48FC-9442-2E9C98993654Q41928655-2D44632D-3646-4926-8C67-53C78A6BE607Q52625005-4156D839-541B-4904-ACE5-5294208D8348Q57059911-20E5E91D-432D-4582-81DB-08CB6890FB27Q59351260-DCCC64D5-31E9-48B2-910A-7D9710C7C165Q63916866-9603727E-3D9E-4ADF-9AAB-AA4645DE0A34Q63916875-FD0C113D-6F29-47E1-BC5D-8157B616CA36Q90440247-870C3F26-7580-4B24-98B3-5BC6E131A191
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stéphanie Reynard
@ast
Stéphanie Reynard
@en
Stéphanie Reynard
@es
Stéphanie Reynard
@nl
type
label
Stéphanie Reynard
@ast
Stéphanie Reynard
@en
Stéphanie Reynard
@es
Stéphanie Reynard
@nl
prefLabel
Stéphanie Reynard
@ast
Stéphanie Reynard
@en
Stéphanie Reynard
@es
Stéphanie Reynard
@nl
P106
P21
P31
P496
0000-0002-8508-5167